Abstract
PET and SPECT are very sensitive techniques to detect in-vivo nigrostriatal degeneration
in Parkinson's disease, even in the pre-motor phase of the disease. Furthermore, these
techniques are able to measure disease progression. However, caution must be used
in the interpretation of studies in which therapeutic effects in Parkinson's disease
were also monitored by serial imaging of nigrostriatal neurons, as disparity between
imaging and clinical outcomes has been reported in several clinical studies.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the Neurological SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism [review].Eur J Nucl Med. 1999; 26: 171-182
- Noninvasive assessment of aromatic l-amino acid decarboxylase activity in aging rhesus monkey brain in vivo.Synapse. 2001; 39: 58-63
- In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.Ann Neurol. 2000; 47: 493-503
- Whole-body biodistribution and radiation dosimetry of 18F-FP-(+)-DTBZ (18F-AV-133): a novel vesicular monoamine transporter 2 imaging agent.J Nucl Med. 2010; 51: 1480-1485
- [123I]SPECT shows a pronounced decline of striatal labelling in early and advanced Parkinson's disease.J Neurol Neurosurg Psychiatry. 1997; 62: 133-140
- Farde L Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study.Eur J Nucl Med Mol Imaging. 2006; 33: 657-668
- A follow-up study on 6-[18F]fluoro-l-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen.Mov Disord. 2009; 24: 1009-1015
- A phase I study of aromatic l-amino acid decarboxylase gene therapy for Parkinson's disease.Mol Ther. 2010; 18: 1731-1735
- Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell.Ann Neurol. 2001; 50: 34-41
- Idiopathic hyposmia as a preclinical sign of Parkinson's disease.Ann Neurol. 2004; 56: 173-181
- Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease.J Neurol Neurosurg Psychiatry. 2010; 81: 396-399
- The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins.Ann Neurol. 1999; 45: 577-582
- Ageing and Parkinson's disease: substantia nigra regional selectivity.Brain. 1991; 114: 2283-2301
- Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism.Ann Neurol. 1994; 36: 759-764
- An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease.Brain. 1996; 119: 585-591
- Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.J Neurol Neurosurg Psychiatry. 1998; 64: 314-319
- [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression.Neurology. 2001; 57: 2089-2094
- Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study.Mov Disord. 2002; 17: 45-53
- [123I]β-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease.J Neurol Neurosurg Psychiatry. 2003; 74: 294-298
- PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.Brain. 2005; 128: 2777-2785
- Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.J Nucl Med. 1998; 39: 1879-1884
- Reproducibility and discriminating ability of fluorine-18-6-fluoro-l-Dopa PET in Parkinson's disease.J Nucl Med. 1996; 37: 421-426
- Dopamine transporter imaging with [123I]FP-CIT SPECT: potential effects of drugs.Eur J Nucl Med Mol Imaging. 2008; 35: 424-438
- Seasonal effects on human striatal presynaptic dopamine synthesis.Neuroscience. 2010; 30: 14691-14694
- Levodopa and the progression of Parkinson's disease.N Engl J Med. 2004; 351: 2498-2508
- Neuroprotection and imaging studies in Parkinson's disease.Parkinsonism Relat Disord. 2009; 15: S33-S37
- Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.JAMA. 2002; 287: 1653-1661
- Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.Ann Neurol. 2003; 54: 93-101
- Pelmopet Study Group. Results of a 3-year randomized, double blind, PET controlled study of pergolide vs levodopa as monotherapy in early Parkinson's disease (PELMOPET-trial).J Neurosci. 2001; 187: 444
- Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation.J Neurol Neurosurg Psychiatry. 2005; 76: 1217-1221
- Dopamine transporter imaging and the effects of deep brain stimulation in patients with Parkinson's disease.Eur J Nucl Med Mol Imaging. 2007; 34: 508-516
- Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease.Nat Med. 2003; 9: 589-595
- Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.Ann Neurol. 2006; 59: 459-466
- Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.Lancet Neurol. 2008; 7: 400-408
- Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.Lancet Neurol. 2010; 9: 1164-1172
- Safety and tolerability of putaminal AADC gene therapy for Parkinson disease.Neurology. 2009; 73: 1662-1669
- A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease.Ann Neurol. 2003; 54: 403-414
- Dopamine cell implantation in Parkinson's disease: long-term clinical and 18F-FDOPA PET outcomes.J Nucl Med. 2010; 51: 7-15
- Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue.Mov Disord. 2003; 18: 928-932
- Long-term assessment of striatal dopamine transporters in Parkinsonian patients with intrastriatal embryonic mesencephalic grafts.Eur J Nucl Med Mol Imaging. 2006; 33: 407-411
- Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain.Nat Med. 2005; 11: 703-704
Article info
Publication history
Published online: August 16, 2011
Accepted:
July 19,
2011
Received in revised form:
June 3,
2011
Received:
March 14,
2011
Identification
Copyright
© 2011 Elsevier B.V. Published by Elsevier Inc. All rights reserved.
